The differential nAE risks we observed among various cancer types—with elevated rates in skin, kidney, and nervous system malignancies—likely reflect these distinct inflammatory landscapes that create varying propensities for cross‐reactive immune responses targeting neural antigens following PD‐1 blockade. The gene discussed is PDCD1; the disease is cancer.